7241 results about "Blood serum" patented technology

The invention relates to the field of biological medicine, in particular to a stapled peptide targeting RAS-Raf protein interaction and application of the stapled peptide, the stapled peptide is obtained in the mode that Ac-SLHDCLMKALKVR-NH2 and Ac-SLHDCLMKALKVRGL-NH2 serve as peptide chain templates, amino acid at the i site and amino acid at the (i + 4) site are replaced with S5 and cyclized, and the nitrogen terminal is further modified with stearic acid. The stapled peptide can effectively inhibit proliferation and migration of tumor cells; the serum stability is high, and meanwhile, the cell transmembrane capability is excellent, so that target protein in cells can be better targeted, and the biological function of the target protein can be exerted. Therefore, the alphaH helical conformation of the RBD of the RAF can be stabilized through the stapled peptide and a nitrogen-terminal fatty acid modification strategy, the membrane permeability and stability of the RAF are improved, the binding force of the RAF and RAS is further improved, and proliferation and migration of various tumor cells are inhibited.

The invention provides an anti-human serum albumin nano antibody and application thereof, and belongs to the technical field of antibodies. The invention provides an anti-human serum albumin nano antibody HSA-32 with relatively high affinity, and the anti-human serum albumin nano antibody HSA-32 is subjected to humanized transformation, so that three obtained humanized anti-human serum albumin nano antibodies can be used for reducing the immunogenicity of the HSA-32 and improving the immunogenicity of the HSA-32; and high specificity and high affinity of combination with the human serum albumin and stability and solubility of the antibody are maintained. The anti-human serum albumin nano antibody can be used for separation, purification and detection of human serum albumin and separation and purification of polypeptide, protein or antibody drugs fused with the anti-human serum albumin nano antibody. Meanwhile, the anti-human serum albumin nano-antibody can effectively prolong the half-life period of polypeptide, protein and antibody drugs fused with the anti-human serum albumin nano-antibody, and can be used for developing long-acting polypeptide, protein or antibody drugs.

The present invention discloses a human serum albumin-targeting nanobody and its application. A variety of human serum albumin-targeting nanobodies that can be used to construct long-acting fusion protein drugs and their immune screening methods are disclosed. The antibody is composed only of the heavy chain variable region and can be fused and expressed with therapeutic proteins or polypeptide drugs such as interleukin, interferon, and tumor necrosis factor in an Escherichia coli expression system. The fusion protein has the activity of specifically binding to human serum albumin, has a relatively high affinity, can effectively extend the drug half-life, and does not affect the biological activity of the recombinant protein drug at the same time.

The invention discloses a bovine serum albumin combined nano antibody and a preparation method and application thereof, the amino acid sequence of the bovine serum albumin combined nano antibody Nb1 is shown as SEQ.ID No.1, the nano antibody Nb not only has high affinity to bovine serum albumin, but also has good binding activity to both human serum albumin and mouse serum albumin, and the nano antibody Nb has high affinity to human serum albumin and mouse serum albumin. And the antibody has a relatively good broad-spectrum application range, and can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like.

The invention relates to the technical field of medical diagnosis, and discloses a DCM early noninvasive analysis method based on multi-radiomics and serum markers. Collecting image data through a multi-modal medical imaging device, and collecting serum marker data through a blood detection device; respectively generating a radiomics feature set and a serum marker time sequence feature set by using a multi-scale feature extraction algorithm and a time sequence analysis model; fusing the features by adopting a dynamic weighted fusion strategy to generate a joint feature matrix; inputting the model into a pre-trained multi-task deep learning model to predict a DCM risk probability; and finally, based on a genetic algorithm, optimizing the diagnosis decision tree and outputting an early DCM diagnosis result. The method is noninvasive and accurate, and can effectively improve the early diagnosis accuracy of DCM.

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention relates to the technical field of tumor risk assessment, and discloses a multi-modal deep learning-based ovarian adnexal tumor risk grading system, which comprises a multi-modal data acquisition module for acquiring ultrasonic image data, CA125 serum concentration data and gold standard data of an ovarian adnexal tumor patient; the ultrasonic image segmentation module is used for carrying out automatic positioning and structured segmentation on a focus area of the ultrasonic image by adopting self-adaptive bidirectional displacement; the multi-modal feature extraction module is used for extracting an O-RADS vector and a CEUS vector according to the focus area mask of the segmented image, and carrying out numerical value normalization processing on the CA125 serum concentration data to obtain a standardized feature vector; the multi-modal feature fusion module carries out feature fusion to obtain OCC-US vector representation; and the risk grading decision module is used for classifying the OCC-US vector representation and outputting an OCC-US score and a benign and malignant risk grade. According to the invention, the diagnosis precision and reliability of the ovarian adnexal tumor are improved.

The present invention provides a serum-free culture medium for in vitro suspension culture of porcine muscle stem cells and its application, which can help porcine muscle stem cells expand and be suspended under serum-free and carrier-free conditions. Compared with traditional porcine muscle stem cell culture protocols and culture media, this serum-free suspension culture medium enables porcine muscle stem cells to be cultured continuously at high densities in both batch and fed-batch culture processes under serum-free and carrier-free suspension culture conditions, while maintaining high cell viability and achieving a peak cell density of 1×10 7 The beneficial effect of the present invention is to effectively solve the problem of serum-free and carrier-free efficient suspension expansion of cell cultured meat seed cells, and provide a technical and raw material basis for the industrial production of cell cultured meat.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention relates to the technical field of biomarkers, in particular to a blood biomarker combination for prediction and auxiliary diagnosis of ovarian reserve hypofunction (DOR), a corresponding detection kit and application of the blood biomarker combination. According to the invention, the content change of the nicotinamide mononucleotide (NMN) and the metabolite combination thereof in serum or plasma is screened for the first time and can be used as a detection index for predicting the ovarian reserve function decline. Based on the biomarker combination, the invention further provides an in-vitro detection kit containing a related standard substance, an internal standard solution and an extracting solution, and a data analysis method combined with a random forest model, so that an individual with a normal ovarian reserve function and an individual with hypofunction can be accurately distinguished. The method is noninvasive, simple, convenient, high in sensitivity and suitable for early recognition and layered screening of clinical ovarian reserve hypofunction.

The invention discloses a porcine muscle stem cell line capable of being cultured in vitro for a long time and application of the porcine muscle stem cell line, and belongs to the technical field of stem cells and cell culture meat. The porcine muscle stem cell line is prepared by the following steps: performing CDKN2A gene knockout on porcine muscle stem cells by using a CRISPR / Cas9 gene editing technology, performing monoclonal screening and genotype identification to obtain a cell strain with successful CDKN2A knockout, and then performing carrier-free and serum-free suspension culture domestication on the cell strain. And a carrier-free and serum-free porcine muscle stem cell line capable of being subjected to in-vitro long-term suspension culture is obtained. Verification shows that the CDKN2A knockout porcine muscle stem cell line subjected to carrier-free and serum-free suspension culture domestication not only can be subjected to carrier-free and serum-free suspension culture in a shake flask for a long time, but also can maintain a good differentiation characteristic. The porcine muscle stem cell line which can be cultured on a large scale, is derived from edible animals and can be cultured in vitro for a long time is created, and excellent cell resources are provided for commercial production of cultured meat.

The invention discloses a probiotic with the depression improving effect and a microecological preparation and application thereof, and is characterized in that the probiotic comprises lactobacillus mucus PC17 with the preservation number of CGMCC No.33866, the active ingredients of the lactobacillus microecological preparation comprise thalli of the lactobacillus mucus PC17, and a preparation method of the microecological preparation comprises the following steps: adding the lactobacillus mucus PC17 into the lactobacillus mucus PC17, uniformly mixing the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17 and the lactobacillus mucus PC17 The lactic acid bacteria are inoculated into a fermentation culture medium according to a volume ratio of 1-5% to prepare the lactic acid bacteria microecological preparation, can be used for preparing antidepressant drugs, and has the advantages of being capable of promoting RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reducing the levels of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and corticotropin in serum, and improving the antidepressant activity of the antidepressant drugs. The levels of aminobutyric acid and brain-derived neurotrophic factors in serum are improved, and the depression-like behaviors of CUMS depression model mice are obviously improved.

The invention discloses tetrapeptide KA4 with an anti-fatigue function as well as a preparation method and application of the tetrapeptide KA4, and belongs to the technical field of biology. The tetrapeptide KA4 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is KYPA, and the tetrapeptide KA4 has strong binding capacity with KEAP1, AMPK and LDH, can significantly reduce the serum lactic acid content of a fatigue model mouse and significantly increase the load swimming time of the fatigue model mouse, has an anti-fatigue function, and can be applied to development of functional food for relieving fatigue.

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention discloses a bran coat polypeptide GR-12 with an immunoregulation function and an application of the bran coat polypeptide GR-12, and the amino acid sequence of the bran coat polypeptide is Gly-Gln-Pro-Trp-Pro-Pro-Ala-Ser-Phe-Ala-Cys-Arg (GQPWPPASFACR, which is called GR-12 for short). Experiments find that the GR-12 can significantly enhance the proliferation activity and phagocytic activity of macrophages RAW264.7 and promote the macrophages RAW264.7 to secrete cytokines; meanwhile, it is found that the GR-12 can significantly enhance the immunomodulatory function of an immunosuppressive mouse induced by cyclophosphamide, specifically, the body weight, thymus index and spleen index of the immunosuppressive mouse are significantly recovered; and the secretion of cytokines and immune globulins in mouse serum is obviously increased. The bran coat polypeptide GR-12 is expected to be further researched and developed into a related medicine product with an immune regulation function, and has a wide application prospect.

The invention relates to the technical field of blood potassium detection, in particular to a blood potassium detection paper-based sensor and a preparation method and application thereof.The sensor is obtained by integrating a substrate, a sensing electrode and a whole blood microfluid channel, and the sensing electrode is located between the substrate and the whole blood microfluid channel; the whole blood microfluid channel comprises a serum diffusion area, a whole blood separation area positioned above the serum diffusion area and a blood potassium detection area positioned below the serum diffusion area; a blood separation membrane is also arranged in the whole blood separation area; the substrate is qualitative filter paper, and the sensing electrode comprises an all-solid-state PBA working electrode and an Ag / AgCl reference electrode; compared with the prior art, calibration is not needed when potassium ions in whole blood are detected, the whole blood sample can be directly used, centrifugal separation is not needed, the detection speed is increased, the hemolysis problem of the whole blood sample in blood potassium detection can be avoided, and the detection sensitivity, accuracy and stability are further improved.

The invention discloses a construction method and application of an electrochemical luminescence (ECL) antifouling sensor based on zwitter-ion hydrogel, and belongs to the technical fields of photoelectric sensing analysis, interface antifouling and environmental science. According to the invention, the hydrogel based on sulfobetaine methacrylate zwitterions and bovine serum albumin is used as the antifouling coating, so that the adsorption of biological proteins and bacteria is effectively hindered, and the service life of the sensor is prolonged. Meanwhile, the interior label Au (at) luminol is packaged in the antifouling hydrogel, so that the integration of interface antifouling and ratio detection is realized, the detection accuracy is improved, and the construction process of the ECL sensor is simplified. The constructed ECL anti-pollution sensor has high sensitivity to chloramphenicol detection, the detection limit is 0.39 pM, and the ECL anti-pollution sensor is suitable for trace detection of antibiotics in seawater.

The present invention belongs to the field of biological detection technology, and specifically relates to an anti-monkey C-reactive protein monoclonal antibody, an enzyme-linked immunosorbent assay kit and its application. Named CRP-13, CRP-13 includes a heavy chain variable region and a light chain variable region; the heavy chain variable region has three complementary determining regions CDR-H1 to CDR-H3, and the amino acid sequences are shown in SEQ ID NO.6-SEQ ID NO.8; the light chain variable region has three complementary determining regions CDR-L1 to CDR-L3, and the amino acid sequences are shown in SEQ ID NO.9-SEQ ID NO.11. The monoclonal antibody of the present invention can specifically bind to monkey C-reactive protein with high specificity. The above monoclonal antibody can be used to screen a paired monoclonal antibody, and a monkey C-reactive protein enzyme-linked immunosorbent assay kit is obtained based on the combination of the monoclonal antibodies, which can detect the content of monkey C-reactive protein in monkey serum, plasma or tissue fluid.

The present invention relates to the technical field of microorganisms. Disclosed are lacticaseibacillus paracasei and a postbiotic product prepared therefrom, and a use of both. The present invention provides lacticaseibacillus paracasei (Latin name) YJS05199, which has the preservation number of GDMCC No.63668, and was preserved in Guangdong Microbial Culture Collection Center on 19 July 2023. The present invention further provides a postbiotic prepared by applying the lacticaseibacillus paracasei. The lacticaseibacillus paracasei and the postbiotic prepared therefrom have a bacteriostatic effect, can inhibit the weight gain of a mouse fed with high-fat diets, reduce the adipose tissue weight and the blood glucose concentration, and can remarkably reduce the levels of TG, TC, and LDL-C in serum of the mouse. Thus, the lacticaseibacillus paracasei and the postbiotic prepared therefrom have great application prospects in preparation of products for preventing or treating obesity and related diseases or in preparation of bacteriostatic products.

The invention provides an exosome, a mesenchymal stem cell and application of the exosome and the mesenchymal stem cell in treatment of type 2 diabetes mellitus, and belongs to the technical field of biological medicine. The exosome secreted by the umbilical cord mesenchymal stem cells of the composite pretreatment group is used for treating the type 2 diabetes mellitus, and the obvious advantages are shown. Compared with a model control group, the exosome has the advantages that the glucose tolerance of diabetic rats treated by the exosome is obviously improved, the blood glucose value is reduced by about 47.5% within 120 minutes, the area under a blood glucose curve (AUC) is reduced by about 50.5%, the serum insulin is increased by about 147.7%, insulin secretion is effectively promoted, the glycosylated hemoglobin level is obviously reduced, and the long-term blood glucose control effect is good. By integrating various indexes, the exosome obtained by the composite pretreatment scheme provided by the invention has a remarkable effect of improving the illness state of rats with type 2 diabetes mellitus, provides a new effective strategy for treatment of type 2 diabetes mellitus, and shows a good application prospect.

The invention provides cat serum albumin and application thereof, and relates to the technical field of protein engineering. According to the invention, mutation is carried out on the cat serum albumin for the first time to obtain a beneficial mutation site, so that the cat serum albumin mutant which can be highly expressed in a pichia pastoris system is obtained. In addition, the cat serum albumin mutant I31L also has the effect of treating ascites due to cirrhosis, and the treatment effect is obviously higher than that in the prior art. A new biological material is provided for application of the cat serum albumin, and a foundation is laid for genetic engineering modification of the cat serum albumin.

The disclosure provides technologies that permit detection and / or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e.g., blood, serum, etc.). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials (e.g., brain-derived proteins, neuron-derived extracellular vesicles, and / or cell-free DNA) in readily-sampled systemic liquids.

The invention belongs to the field of biological detection, and discloses a kit for detecting cervical cancer and application of the kit. The kit comprises an elisa plate coated with a captured antibody, an HRP labeled antibody, an antigen standard substance, a washing solution, a developing solution and a stop solution, the heavy chain amino acid sequence of the monoclonal antibody CPT1A-1 of the anti-CPT1A protein in the capture antibody is as shown in SEQ ID NO. 1, and the light chain amino acid sequence is as shown in SEQ ID NO. 2; the heavy chain amino acid sequence of the monoclonal antibody CPT1A-2 of the anti-CPT1A protein in the HRP labeled antibody is as shown in SEQ ID NO.3, and the light chain amino acid sequence of the monoclonal antibody CPT1A-2 of the anti-CPT1A protein in the HRP labeled antibody is as shown in SEQ ID NO.4. The kit for diagnosis of cervical cancer provided by the invention has strong specificity, can specifically detect the content of CPT1A protein in serum, has good stability, and has good application prospects.

The invention discloses a milk-derived broad-spectrum antibacterial peptide and application thereof, and relates to the technical field of biology. The amino acid sequence of the antibacterial peptide is as shown in any one of SEQ ID NO.2-6. Five novel antibacterial peptides are obtained by carrying out symmetrical structure design and amino acid mutation on the basis of a template peptide, and tests find that the five novel antibacterial peptides have broad-spectrum antibacterial activity which is obviously higher than that of the template peptide, and basically have no cytotoxicity. Wherein the geometric mean (GM) of the minimum inhibitory concentration can reach 3.60, and the therapeutic index (TI) can reach 71.11. The antibacterial peptide prepared by the invention still keeps good antibacterial activity in physiological salt concentration and protease environment, has certain serum stability, and has higher application value; in addition, the antibacterial peptide has a good inhibition effect on the formation of a bacterial biofilm, and has a synergistic effect with traditional antibiotics.

The invention discloses a serum-free culture system and culture method of NK cells. The invention firstly discloses a serum-free culture system of the NK cells, wherein the serum-free culture system comprises a coating solution, an amplification culture medium, an activation culture medium and autologous plasma; the invention further discloses a culture method for NK cells by using the serum-free culture system. The method for culturing the NK cells by using the serum-free culture system disclosed by the invention reduces the culture cost of the NK cells, can simply, quickly, efficiently and safely obtain a large number of NK cells with high activity, high purity and strong killing ability in vitro, provides a better cell source for clinical application of the NK cells, and promotes further development of an NK cell treatment technology.

The invention relates to the technical field of hemodialysis monitoring, and provides a hemodialysis on-line monitoring system and method, and the system comprises a data acquisition module which is used for collecting blood physiological parameters in a dialysis pipeline in real time; the blood component analysis module is connected with a blood loop of the dialysis machine and is used for detecting serum iron, ferritin and ferritin saturation indexes on line; and the data processing module is used for calculating the risk index of anemia, evaluating the iron utilization rate, constructing a model for measuring the iron deficiency erythropoiesis trend according to the collected and analyzed data, and training and optimizing the model. According to the method, individual parameters of patients are fused, personalized calculation is performed for iron metabolism rates and dialysis parameters of different patients, and data such as iron content, blood flow and dialysis fluid volume are acquired online in real time, so that iron concentration and infusion rate are accurately matched with real-time iron metabolism requirements of the patients, and anemia of the patients in the dialysis process is reduced.

The invention includes a mutant Taq polymerase, which can effectively amplify a target sequence under conditions of salt concentration(s) similar to body fluids, including blood, serum or plasma preserved with sodium citrate. The mutant Taq polymerase, or a biologically active fragment thereof, has one or more substitutions differing from the wild type as shown in Table I.

The invention belongs to the technical field of monoclonal antibody preparation, and particularly relates to a human-mouse chimeric monoclonal antibody for resisting human G protein-coupled receptor family member 1 (LGI1 protein) as well as a product and application of the human-mouse chimeric monoclonal antibody. The variable regions of the heavy chain and the light chain of the human-mouse chimeric monoclonal antibody of the anti-human LGI1 protein come from mice, and the constant regions of the heavy chain and the light chain of the human-mouse chimeric monoclonal antibody are human antibody constant regions, so that the human-mouse chimeric monoclonal antibody can replace the function of serum to a certain extent on the basis of retaining parent activity to the greatest extent; meanwhile, the technical problems that the Fc region of the existing anti-human LGI1 protein monoclonal antibody cannot react with the anti-human IgG antibody, the sensitivity difference among multiple batches of antibodies is large, and batch production cannot be realized can be solved. Furthermore, the human-mouse chimeric monoclonal antibody of the anti-human LGI1 protein can be used for detecting the LGI1 protein and an LGI1 autoantibody.

The invention provides a serum-free culture medium for in-vitro suspension culture of porcine muscle stem cells and application of the serum-free culture medium. The serum-free culture medium can help the porcine muscle stem cells to be subjected to suspension enlarged culture under serum-free and carrier-free conditions. Compared with a traditional porcine muscle stem cell culture scheme and culture medium, the serum-free suspension culture medium has the advantages that high-density continuous culture of porcine muscle stem cells can be realized in a batch culture process and a fed-batch culture process under the serum-free carrier-free suspension culture condition, high cell viability is maintained, and the survival rate of the porcine muscle stem cells is increased. The peak density of the cells reaches 1 * 10 < 7 > cells / mL or above, and the cell viability is maintained to be 90% or above. The method has the beneficial effects that the problem of serum-free carrier-free efficient suspension amplification of the seed cells of the cell culture meat is effectively solved, and a technical and raw material basis is provided for industrial production of the cell culture meat.